FierceBiotech24d
Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities
CytomX still believes in the core concept. CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager “We continue T-cell engager discovery work with Amgen,” McCarthy said.
Hosted on MSN2mon
Bay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staff
CytomX Therapeutics, a once high-flying biotech firm, is laying off 40% of its staff ... are in development with industry giants like Amgen, Bristol Myers Squibb and Moderna.
Hosted on MSN1mon
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs
Amgen stock reversed higher Wednesday after the biotech behemoth said the Food and Drug Administration placed one of its obesity treatments on clinical hold. This means Amgen can't run testing of ...
SFGate2mon
Bay Area biotech firm CytomX, once worth $1.2 billion, lays off 40% of staff
CytomX Therapeutics, a once high-flying biotech firm, is laying off 40% of its staff ... are in development with industry giants like Amgen, Bristol Myers Squibb and Moderna.